The role of EZH2 in tumour progression
Open Access
- 20 December 2011
- journal article
- review article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 106 (2), 243-247
- https://doi.org/10.1038/bjc.2011.551
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Aberrations of EZH2 in CancerClinical Cancer Research, 2011
- Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancerMolecular Cancer, 2011
- EZH2 Promotes Expansion of Breast Tumor Initiating Cells through Activation of RAF1-β-Catenin SignalingCancer Cell, 2011
- Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2Nature, 2010
- EZH2 Mutations: Mutating the Epigenetic Machinery in Myeloid MalignanciesCancer Cell, 2010
- The PRC1 Polycomb group complex interacts with PLZF/RARA to mediate leukemic transformationGenes & Development, 2009
- Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1Oncogene, 2008
- Repression of E-cadherin by the polycomb group protein EZH2 in cancerOncogene, 2008
- Akt-Mediated Phosphorylation of EZH2 Suppresses Methylation of Lysine 27 in Histone H3Science, 2005
- EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancerThe EMBO Journal, 2003